Interactive Virtual Assistance for Self-Care Management and Mental Health Promotion in Type 2 Diabetes

BACKGROUD: Health technology is an important tool in the aging process, which may improve the health condition and self-esteem of the elderly, in addition to offering new opportunities and challenges. In this scenario, the use of virtual interaction systems emerge as promising alternatives for the old adults, which often deals with the lack of social interaction, cognitive decline and decline in functional capacity, making the control of chronic diseases, such as diabetes, a challenge.

OBJECTIVES: This project aims to evaluate the effectiveness of using an interactive virtual assistance system in mental health parameters, glycemic profile and diabetes selfcare behavior in elderly people with diabetes.

METHODS: A randomized clinical trial is proposed, for an intervention that includes 3 months of use of the Smart Speaker Echo Dot system, programmed to provide reminders, stimulate treatment records and maintain healthy habits. Outcomes assessed will include parameters of mental health and diabetes control.

Study Overview

Study Type

Interventional

Enrollment (Actual)

112

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Rio Grande Do Sul
      • Porto Alegre, Rio Grande Do Sul, Brazil, 90619-900
        • Pontificia Universidade Católica do Rio Grande do Sul

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion:

  • Being 65 years of age or older;
  • Having a diagnosis of type 2 diabetes;
  • Residing in Porto Alegre or metropolitan region;
  • Presenting availability of Wi-Fi connection at home; and
  • Presenting availability to participate in the proposed face-to-face evaluation and accept receiving one visit for installation of the device.

Exclusion:

  • Having an interactive virtual home assistance device at the time of enrollment;
  • Having cognitive impairments or severe hearing impairments that prevent adequate interaction with outcome assessors and the application of follow-up questionnaires; or
  • Residing in regions of difficult access.

Recruitment:

Study subjects will be recruited through two different strategies:

  • Screening of records of the outpatients clinics of Hospital São Lucas (HSL)
  • Social media advertising, specially in Instagram®

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A
12 weeks of daily interactions with Smart Speaker EchoDot 3rd Gen (Amazon Echo®).

Participants will receive the Smart Speaker EchoDot 3rd Gen (Amazon Echo®) device (i.e., Alexa) for home use, installed during a home visit following the study enrollment. In addition to the usual functionality of the system, the device will be programmed using a standard model developed by the research team, applied to each patient. The proposed model involves automatic interactions between the device and the patient, comprising:

  1. Medication reminders
  2. Glucose test reminders:
  3. Educational health tips
  4. Weekly educational podcasts
  5. Good morning and good night routine
Other: Group B
12 weeks of maintenance of usual care.
Participants will maintain usual care during the study period and will receive a booklet with general advice following enrollment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Screening for depression, anxiety and common mental health disorders in elderly
Time Frame: Change from baseline to 12 weeks
For mental health screening, the Self Report Questionnaire (SRQ 20) will be used, translated into Portuguese and validated for the Brazilian population. It is a questionnaire with 20 questions specially developed for the screening of depression, anxiety em common mental health disorders in the elderly. Higher scores indicating more mental distress.
Change from baseline to 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glycemic control: glycated hemoglobin (HbA1c) assessment
Time Frame: Change from baseline to 12 weeks
To assess glycemic control, the dosage of glycated hemoglobin (HbA1c) will be performed by high performance liquid chromatography, a measure that estimates the average glycemic control of the three months before the exam.
Change from baseline to 12 weeks
Variation in systolic blood pressure
Time Frame: Change from baseline to 12 weeks
Systolic blood pressure assessment (mmHg)
Change from baseline to 12 weeks
Variation in diastolic blood pressure
Time Frame: Change from baseline to 12 weeks
Diastolic blood pressure assessment (mmHg)
Change from baseline to 12 weeks
Variation in total cholesterol
Time Frame: Change from baseline to 12 weeks
Total cholesterol (mg/dL)
Change from baseline to 12 weeks
Adherence parameters and self-care in the treatment of diabetes
Time Frame: Change from baseline to 12 weeks
To assess adherence and self-care related to diabetes, the Self-Care Inventory Revised (SCI-R) questionnaire will be used, a version translated into Portuguese and validated for the Brazilian population. It is a questionnaire with 11 questions and answer options based on the 5-point Likert scale and which reflects the follow-up of treatment recommendations and lifestyle habits related to diabetes care in the2 months prior to the application. Higher scores reflect greater adherence and self-care.
Change from baseline to 12 weeks
Evaluation of quality of life
Time Frame: Change from baseline to 12 weeks
Quality of Life will be assessed at baseline and after 12 weeks using the Short Form Health Survey (SF-36) questionnaire.
Change from baseline to 12 weeks
Perception of stress:
Time Frame: Change from baseline to 12 weeks
Quality of Life will be assessed at baseline and after 12 weeks using the Perceived Stress Scale (PSS) questionnaire.
Change from baseline to 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 20, 2023

Primary Completion (Actual)

May 17, 2024

Study Completion (Actual)

May 17, 2024

Study Registration Dates

First Submitted

March 14, 2022

First Submitted That Met QC Criteria

April 8, 2022

First Posted (Actual)

April 15, 2022

Study Record Updates

Last Update Posted (Actual)

May 22, 2024

Last Update Submitted That Met QC Criteria

May 20, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

Clinical Trials on Smart Speaker Echo Dot

Subscribe